SEOM guidelines for the management of Malignant Melanoma 2015
| Autor: | Ainara Soria, Alfonso Berrocal, Maria Gonzalez Cao, I. Márquez, Salvador Martin Algarra, A. G. Castano, J. L. G. Larriba, Ana Arance, Enrique Espinosa, José Antonio López Martín |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
medicine.medical_specialty Cancer Research medicine.medical_treatment Clinical Guides in Oncology Medical Oncology Internal medicine Biopsy medicine Adjuvant therapy Combined Modality Therapy Humans neoplasms Melanoma Early Detection of Cancer Societies Medical Adjuvant Neoplasm Staging Clinical Trials as Topic medicine.diagnostic_test business.industry Disease Management General Medicine Immunotherapy b-raf Sentinel node medicine.disease Prognosis digestive system diseases Surgery Radiation therapy Practice Guidelines as Topic Metastatic business |
| Zdroj: | Clinical & Translational Oncology |
| ISSN: | 1699-3055 |
| Popis: | All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy. Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink